Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma.

Cell Rep Med · 2023 · PMC10772345 · PMID 38052215

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A direct PFS association analysis in the NRF2 high versus NRF2 low subgroups in the tislelizumab plus chemotherapy arm showed a trend similar to the NRF2 mutation status analysis results, although this was not statistically significant (HR = 0.90, 95% CI 0.50–1.61, p = 0.445; Figure S4 B).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.